MEDO INC

Medo Inc. is a healthcare technology company focused on revolutionizing ultrasound imaging through AI-driven solutions, enhancing diagnostic capabilities and operational efficiency in medical practices. Founded in 2017 and headquartered in Edmonton, Canada, Medo Dx Pte. Ltd.

specializes in developing innovative ultrasound imaging solutions. The company was recently acquired by Exo Imaging, Inc. on July 26, 2022, as part of a strategic move to integrate its AI algorithms with Exo's advanced hardware and workflow technologies. Jeevesh Kapur, the founder of Medo Dx, has a history of entrepreneurial ventures, contributing to the company's growth and innovation.

Since its inception, the firm has completed 6 deals and has raised a total of USD 1. 00 mn, with the latest round being a Series A funded by Great Noble International and elev8. vc, resulting in a current company valuation of USD 20. 83 mn.

Medo Inc. offers advanced software platforms that enhance operational efficiency across various industries, particularly in healthcare. Their solutions streamline workflow processes, facilitate real-time data analytics, and improve productivity. The core offerings target small to medium-sized enterprises (SMEs) and large corporations, addressing challenges like inefficient resource allocation and fragmented communication.

The company has expanded its services into North America and Western Europe, providing integrated technological solutions that optimize operational frameworks for clients. The company generates revenue through annual subscription models that grant clients access to its full suite of software tools and ongoing support. In addition to subscriptions, Medo Dx collaborates with industry partners to provide customized solutions that cater to specific client needs. These partnerships may involve exclusive contracts with pricing tiers based on usage, fostering long-term relationships that ensure continuous value for clients and predictable revenue streams for the firm.

Medo Dx plans to leverage its recent acquisition by Exo Imaging, Inc. to enhance its ultrasound imaging solutions further. The integration of Exo's hardware and workflow technologies with Medo's AI capabilities is expected to lead to the development of new products designed to improve diagnostic accuracy and efficiency. The company aims to expand its market presence in North America and Western Europe by the end of 2023, targeting healthcare providers seeking advanced imaging technologies.

The funding from the Series A round will be utilized to support these initiatives and accelerate product development.